Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A recurrent activating PLCG1 mutation in cardiac angiosarcomas increases apoptosis resistance and invasiveness of endothelial cells.

Cancer research - 1 Nov 2014

Kunze Kristin, Spieker Tilmann, Gamerdinger Ulrike, Nau Kerstin, Berger Johannes, Dreyer Thomas, Sindermann Jürgen R, Hoffmeier Andreas, Gattenlöhner Stefan, Bräuninger Andreas

Abstract excerpt

Primary cardiac angiosarcomas are rare tumors with unfavorable prognosis. Pathogenic driver mutations are largely unknown. We therefore analyzed a collection of cases for genomic aberrations using SNP arrays and targeted next-generation sequencing (tNGS) of oncogenes and tumor-suppressor genes. R...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apoptosis
Share to Endothelial Cells
Share to Heart Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hemangiosarcoma

Share to Neoplasm Invasiveness

Share to Phospholipase C gamma

Share to src Homology Domains

Share to Vascular Endothelial Growth Factor Receptor-2

Source

Identifiers

PMID: 25252913
DOI: 10.1158/0008-5472.CAN-14-1162

Genes

KDR
PLCG1
KIT

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-25252913-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A recurrent activating PLCG1 mutation in cardiac angiosarcomas increases apoptosis resistance and invasiveness of endothelial cells.PMID 25252913Read ↗

Recurrent CIC Gene Abnormalities in Angiosarcomas: A Molecular Study of 120 Cases With Concurrent Investigation of PLCG1, KDR, MYC, and FLT4 Gene Alterations.Semantic proximity Read ↗

Phospholipase C gamma 1 (PLCG1) R707Q mutation is counterselected under targeted therapy in a patient with hepatic angiosarcoma.Semantic proximity Read ↗

Genomic Profiling of Cardiac Angiosarcoma Reveals Novel Targetable KDR Variants, Recurrent MED12 Mutations, and a High Burden of Germline POT1 AlterationsSemantic proximity Read ↗

Recurrent PTPRB and PLCG1 mutations in angiosarcoma.Semantic proximity Read ↗

PIK3CA mutation fortifies molecular determinants for immune signaling in vascular cancers.Semantic proximity Read ↗

Cardiac angiosarcoma: histopathologic, immunohistochemical, and cytogenetic analysis of 10 cases.Semantic proximity Read ↗

Angiogenesis-related gene mutations drive a subset of angiosarcomas.Semantic proximity Read ↗

Case report: whole exome sequencing of primary cardiac angiosarcoma highlights potential for targeted therapies.Semantic proximity Read ↗

Primary mammary angiosarcomas harbor frequent mutations in KDR and PIK3CA and show evidence of distinct pathogenesis.Semantic proximity Read ↗

Constitutively active PIK3CA mutations are expressed by lymphatic and vascular endothelial cells in capillary lymphatic venous malformation.Semantic proximity Read ↗

Frequent protein kinase A regulatory subunit A1 mutations but no GNAS mutations as potential driver in sporadic cardiac myxomas.Semantic proximity Read ↗

Molecular Analysis of Renal/Adrenal Angiosarcomas Reveals High Frequency of Recurrent Genetic Alterations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.